Sutro Biopharma (NASDAQ:STRO) Stock Rating Upgraded by Mizuho

Sutro Biopharma (NASDAQ:STRO) was upgraded by research analysts at Mizuho to a “strong-buy” rating in a report issued on Wednesday, Zacks reports.

Other research analysts have also recently issued reports about the stock. Wedbush reissued an “outperform” rating and set a $60.00 price objective on shares of Sutro Biopharma in a research note on Thursday, August 13th. Wall Street Zen lowered Sutro Biopharma from a “hold” rating to a “sell” rating in a research note on Sunday, June 14th. Citizens Jmp lowered their target price on Sutro Biopharma from $41.00 to $34.00 and set a “market outperform” rating on the stock in a report on Thursday, August 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Sutro Biopharma in a research report on Wednesday, August 5th. Finally, Citigroup reissued a “market outperform” rating on shares of Sutro Biopharma in a report on Thursday, August 13th. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Sutro Biopharma presently has a consensus rating of “Buy” and a consensus target price of $47.30.

Sutro Biopharma Trading Down 0.8%

Shares of NASDAQ STRO opened at $15.48 on Wednesday. The stock has a market cap of $256.66 million, a price-to-earnings ratio of -1.29 and a beta of 1.48. Sutro Biopharma has a 52 week low of $7.15 and a 52 week high of $43.85. The company’s 50-day moving average price is $22.08 and its 200 day moving average price is $26.52.

Sutro Biopharma (NASDAQ:STRO) last announced its earnings results on Wednesday, August 12th. The company reported ($2.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.19) by ($0.14). The business had revenue of $9.84 million for the quarter, compared to the consensus estimate of $11.96 million. As a group, research analysts expect that Sutro Biopharma will post -8.41 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Merck & Co. Inc. purchased a new stake in shares of Sutro Biopharma in the second quarter valued at $9,042,053. Perceptive Advisors LLC purchased a new position in Sutro Biopharma during the first quarter worth about $17,818,000. Affinity Asset Advisors LLC lifted its position in Sutro Biopharma by 42.9% during the first quarter. Affinity Asset Advisors LLC now owns 1,069,519 shares of the company’s stock worth $26,642,000 after buying an additional 321,137 shares during the period. Orbimed Advisors LLC acquired a new stake in Sutro Biopharma in the 1st quarter worth about $19,956,000. Finally, Seven Fleet Capital Management LP acquired a new stake in Sutro Biopharma in the 2nd quarter worth about $5,283,000. Hedge funds and other institutional investors own 96.99% of the company’s stock.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on developing targeted cancer therapies. The company uses its proprietary XpressCF cell-free protein synthesis platform to design and manufacture antibody-drug conjugates (ADCs) and immunostimulatory antibody conjugates intended to selectively target tumor cells while limiting damage to healthy tissue.

Sutro’s pipeline has included luveltamab tazevibulin, also known as luvelta or STRO-002, a folate receptor alpha-directed ADC being investigated for the treatment of ovarian and endometrial cancers.